idarubicinol has been researched along with trypan blue in 1 studies
| Studies (idarubicinol) | Trials (idarubicinol) | Recent Studies (post-2010) (idarubicinol) | Studies (trypan blue) | Trials (trypan blue) | Recent Studies (post-2010) (trypan blue) |
|---|---|---|---|---|---|
| 54 | 10 | 0 | 2,857 | 40 | 414 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, T; Imamura, S; Inai, K; Inoue, H; Kishi, S; Nakamura, T; Nakayama, T; Takemura, H; Ueda, T; Urasaki, Y; Yamauchi, T | 1 |
1 other study(ies) available for idarubicinol and trypan blue
| Article | Year |
|---|---|
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Topics: Antineoplastic Agents; Cell Division; Cell Extracts; Cell Survival; Cytotoxins; Daunorubicin; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Idarubicin; Trypan Blue; Tumor Cells, Cultured | 1998 |